Novel psychoactive substances-related presentations to the emergency departments of the European drug emergencies network plus (Euro-DEN plus) over the six-year period 2014–2019

References

• European Monitoring Centre for Drugs and Drug Addiction. European drug report 2020: trends and developments. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2020. [cited 2022 Feb 1]. https://www.emcdda.europa.eu/system/files/publications/13236/TDAT20001ENN_web.pdf
   Google Scholar
• Tracy DK, Wood DM, Baumeister D. Novel psychoactive substances: types, mechanisms of action, and effects. BMJ. 2017;356:i6848.
   PubMed Web of Science ®Google Scholar
• Gibbons S. Legal highs’–novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin Toxicol (Phila). 2012;50(1):15–24.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. European drug report 2018: trends and developments. Lisbon: Office for Official Publications of the European Communities; 2018. [cited 2022 Feb 1]. https://www.emcdda.europa.eu/system/files/publications/8585/20181816_TDAT18001ENN_PDF.pdf
   Google Scholar
• United Nations Office on Drugs and Crime. World drug report 2018. 2018. [cited 2022 Feb 1]. https://www.unodc.org/wdr2018/en/exsum.html
   Google Scholar
• Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol. 2011;49(8):705–719.
   Web of Science ®Google Scholar
• Logan BK, Mohr ALA, Friscia M, et al. Reports of adverse events associated with use of novel psychoactive substances, 2013–2016: a review. J Anal Toxicol. 2017;41(7):573–610.
   PubMed Web of Science ®Google Scholar
• Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol. 2020;94(4):1085–1133.
   PubMed Web of Science ®Google Scholar
• Wood DM, Ceronie B, Dargan PI. Healthcare professionals are less confident in managing acute toxicity related to the use of new psychoactive substances (NPS) compared with classical recreational drugs. QJM. 2016;109(8):527–529.
   PubMed Web of Science ®Google Scholar
• Wood DM, De La Rue L, Hosin AA, et al. Poor identification of emergency department acute recreational drug toxicity presentations using routine hospital coding systems: the experience in Denmark, Switzerland and the UK. J Med Toxicol. 2019;15(2):112–120.
   PubMed Web of Science ®Google Scholar
• Wood DM, Conran P, Dargan PI. ICD-10 coding: poor identification of recreational drug presentations to a large emergency department. Emerg Med J. 2011;28(5):387–389.
   PubMed Web of Science ®Google Scholar
• Heyerdahl F, Hovda KE, Giraudon I, et al. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations. Clin Toxicol (Phila). 2014;52(10):1005–1012.
   PubMed Web of Science ®Google Scholar
• Wood DM, Heyerdahl F, Yates CB, et al. The European drug emergencies network (Euro-DEN). Clin Toxicol (Phila). 2014;52(4):239–241.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Drug-related hospital emergency presentations in Europe: update from the Euro-DEN Plus expert network. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2020. [cited 2022 Feb 1]. https://www.emcdda.europa.eu/system/files/publications/12725/TD02AY20001ENN.pdf
   Google Scholar
• Grafinger KE, Liechti ME, Liakoni E. Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication. Br J Clin Pharmacol. 2020;86(3):429–436.
   PubMed Web of Science ®Google Scholar
• Potts AJ, Cano C, Thomas SHL, et al. Synthetic cannabinoid receptor agonists: classification and nomenclature. Clin Toxicol (Phila). 2020;58(2):82–98.
   PubMed Web of Science ®Google Scholar
• Hill SL, Najafi J, Dunn M, et al. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the identification of novel psychoActive substances (IONA) study. Clin Toxicol. 2016;54(8):638–643.
   PubMed Web of Science ®Google Scholar
• White JC, Wood DM, Hill SL, et al. Acute toxicity following analytically confirmed use of the novel psychoactive substance (NPS) methiopropamine. A report from the identification of novel psychoActive substances (IONA) study. Clin Toxicol. 2019;57(7):663–667.
   PubMed Web of Science ®Google Scholar
• Blanco G, Vidler D, Roper C, et al. Acute toxicity from the synthetic cathinone N-ethylpentylone (ephylone) in the United Kingdom. Clin Toxicol (Phila). 2021;59:1270–1273.
   PubMed Web of Science ®Google Scholar
• Helander A, Backberg M, Beck O. Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: experiences from the STRIDA project. PLoS One. 2020;15(4):e0232038.
   PubMed Web of Science ®Google Scholar
• Helander A, Backberg M, Hulten P, et al. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. Forensic Sci Int. 2014;243:23–29.
   PubMed Web of Science ®Google Scholar
• Monte AA, Hopkinson A, Saben J, et al. The psychoactive surveillance consortium and analysis network (PSCAN): the first year. Addiction. 2020;115(2):270–278.
   PubMed Web of Science ®Google Scholar
• Partridge E, Alfred S, Camilleri A, et al. Establishing the protocols for the South Australian emergency department admission blood psychoactive testing (EDABPT) programme for drug surveillance. Emerg Med Australas. 2021;33:883–887.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime. World drug report 2020. San Francisco (CA): United Nations; 2020. [cited 2022 Feb 1]. https://wdr.unodc.org/wdr2020/en/index2020.html
   Google Scholar
• Smyth BP, O'Farrell A, Cullen W. Drug-related medical hospital admissions during and after a period of head shop expansion. Eur J Public Health. 2021;31(2):285–291.
   PubMed Web of Science ®Google Scholar
• Webb NE, Wood DM, Greene SL, et al. Change in the new psychoactive substances associated with emergency department acute toxicity presentations associated with the introduction of the UK 2016 psychoactive substances act. Clin Toxicol (Phila). 2019;57(1):36–41.
   PubMed Web of Science ®Google Scholar
• Dines AM, Wood DM, Yates C, et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European drug emergencies network (Euro-DEN). Clin Toxicol (Phila). 2015;53(9):893–900.
   PubMed Web of Science ®Google Scholar
• Henshall DE, Innes CW, Morrison SR, et al. A prospective observational study of emergency department presentations following novel psychoactive substance use. Scott Med J. 2018;63(2):39–44.
   PubMed Web of Science ®Google Scholar
• Tebo C, Mazer-Amirshahi M, Wax P, et al. Characterizing trends in synthetic cannabinoid receptor agonist use from patient clinical evaluations during medical toxicology consultation. J Psychoactive Drugs. 2020;23:1–8.
   Google Scholar
• Maxwell JC. The changing face of synthetic cannabinoids in Texas. J Psychoactive Drugs. 2018;50(4):281–286.
   PubMed Web of Science ®Google Scholar
• Public Health England. Adult substance misuse treatment statistics 2019 to 2020. 2020. [cited 2022 Feb 1]. https://www.gov.uk/government/statistics/substance-misuse-treatment-for-adults-statistics-2019-to-2020/adult-substance-misuse-treatment-statistics-2019-to-2020-report
   Google Scholar
• Ralphs R, Gray P, Sutcliffe OB. The impact of the 2016 psychoactive substances act on synthetic cannabinoid use within the homeless population: markets, content and user harms. Int J Drug Policy. 2021;97:103305.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances in prison. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2018. [cited 2022 Feb 1]. https://www.emcdda.europa.eu/system/files/publications/8869/nps-in-prison.pdf
   Google Scholar
• Public Health England. National poisons information service report 2018/19. 2019. [cited 2022 Feb 1]. https://www.npis.org/Download/NPISAnnualReport2018-19.pdf
   Google Scholar
• Giorgetti A, Busardo FP, Tittarelli R, et al. Post-Mortem toxicology: a systematic review of death cases involving synthetic cannabinoid receptor agonists. Front Psychiatry. 2020;11:464.
   PubMed Web of Science ®Google Scholar
• Kraemer M, Boehmer A, Madea B, et al. Death cases involving certain new psychoactive substances: a review of the literature. Forensic Sci Int. 2019;298:186–267.
   PubMed Web of Science ®Google Scholar
• Fockele C, Armenian P. A cross-sectional emergency department survey of novel psychoactive substance prevalence. Am J Emerg Med. 2017;35(10):1580.
   PubMed Web of Science ®Google Scholar
• Peacock A, Bruno R, Gisev N, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet. 2019;394(10209):1668–1684.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. Drug misuse in England and Wales: year ending. 2020. [cited 2022 Feb 1]. https://www.ons.gov.uk/peoplepopulationandcommunity/crimeandjustice/articles/drugmisuseinenglandandwales/yearendingmarch2020
   Google Scholar
• ESPAD Group. ESPAD report 2019: results from the European school survey project on alcohol and other drugs. Luxembourg: ESPAD Group; 2020. [cited 2022 Feb 1]. https://www.emcdda.europa.eu/system/files/publications/13398/2020.3878_EN_04.pdf
   Google Scholar
• Barratt MJ, Ferris JA, Zahnow R, et al. Moving on from representativeness: testing the utility of the global drug survey. Subst Abuse. 2017;11:1178221817716391.
   Web of Science ®Google Scholar
• Global Drug Survey. Global drug survey 2020: executive summary. 2020. [cited 2022 Feb 1]. https://www.globaldrugsurvey.com/wp-content/uploads/2021/01/GDS2020-Executive-Summary.pdf
   Google Scholar
• Marchei E, Ferri MA, Torrens M, et al. Ultra-high performance liquid chromatography-high resolution mass spectrometry and high-sensitivity gas chromatography-mass spectrometry screening of classic drugs and new psychoactive substances and metabolites in urine of consumers. Int J Mol Sci. 2021;22(8):4000.
   PubMed Web of Science ®Google Scholar
• Bade R, White JM, Chen J, et al. International snapshot of new psychoactive substance use: case study of eight countries over the 2019/2020 New Year period. Water Res. 2021;193:116891.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Drugs in syringes from six European cities: results from the ESCAPE project 2017. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2019. [cited 2022 Feb 1]. https://www.emcdda.europa.eu/system/files/publications/11287/20191061_TD0119176ENN_PDF.pdf
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Final report of the European Drug Emergencies Network (Euro -DEN) March 2015. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2015. [cited 2022 Feb 1]. https://www.emcdda.europa.eu/drugs-library/final-report-european-drug-emergencies-network-euro-den-march-2015_no
   Google Scholar
• Ibrahim-Achi D, Miro O, Galicia M, et al. Spanish research network on drugs in hospital emergency departments - the REDUrHE registry: general analysis and comparisons between weekend and weekday poisonings. Emergencias. 2021;33(5):335–344.
   PubMed Web of Science ®Google Scholar
• Liakoni E, Yates C, Dines AM, et al. Acute recreational drug toxicity: comparison of self-reports and results of immunoassay and additional analytical methods in a multicenter European case series. Medicine (Baltimore). 2018;97(5):e9784.
   PubMed Web of Science ®Google Scholar
• Vallersnes OM, Persett PS, Oiestad EL, et al. Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway. Clin Toxicol (Phila). 2017;55(7):636–644.
   PubMed Web of Science ®Google Scholar
• Davies S, Wood DM, Smith G, et al. Purchasing 'legal highs’ on the internet–is there consistency in what you get? QJM. 2010;103(7):489–493.
   PubMed Web of Science ®Google Scholar
• Brandt SD, Sumnall HR, Measham F, et al. Second generation mephedrone. The confusing case of NRG-1. BMJ. 2010;341:c3564.
   PubMed Web of Science ®Google Scholar
• Ramsey J, Dargan PI, Smyllie M, et al. Buying ‘legal’ recreational drugs does not mean that you are not breaking the law. QJM. 2010;103(10):777–783.
   PubMed Web of Science ®Google Scholar
• Backberg M, Jonsson KH, Beck O, et al. Investigation of drug products received for analysis in the Swedish STRIDA project on new psychoactive substances. Drug Test Anal. 2018;10(2):340–349.
   PubMed Web of Science ®Google Scholar